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Histone deacetylases (HDACs) play a key role in homeostasis of protein acetylation in histone and nonhistone proteins and
in regulating fundamental cellular activities. In this paper we review and discuss intriguing recent developments in the use of
histone deacetylase inhibitors (HDACIs) to combat some critical conditions in an animalmodel of hemorrhagic and septic shock.
HDACIs have neuroprotective, cardioprotective, renal-protective, and anti-inﬂammatory properties; survival improvements have
beensigniﬁcantlyshowninthesemodels.WediscussthetargetsandmechanismsunderlyingtheseeﬀectsofHDACIsandcomment
on the potential new clinical applications for these agents in the future. This paper highlights the emerging roles of HDACIs as
acetylation modulators in models of hemorrhagic and septic shock and explains some contradictions encountered in previous
studies.
1.Introduction
Hemorrhagic shock (HS) is a major cause of morbidity and
mortality among trauma patients. Sepsis or septic shock is
al e a d i n gc a u s eo fm o r t a l i t yi ni n t e n s i v ec a r eu n i t s .E v e ni f
some patients with HS survive the acute episode of blood
loss, they often exhibit a systemic inﬂammatory response
syndrome (SIRS), which is often further complicated by the
subsequent development of septic shock resulting from a
harmful or damaging host response to infection [1]. HS-
induced systemic response shares many features with septic
response [2]. At the molecular level, it has been reported
that both hemorrhage and sepsis lead to an imbalance in
acetylation of proteins and that HDACIs can induce protein
acetylation and restore this balance [3–5].
1.1. Lysine Acetylation and Histone Deacetylase Inhibitors.
Lysine acetylation or Nε-acetylation, identiﬁed initially on
core histones in 1968 [6], is mediated by a group of enzymes
called histone acetyltransferases (HATs) that transfer acetyl
groups from acetyl-coenzyme A to the ε-amino group of
lysines. HATs are counterbalanced by the activity of histone
deacetylases (HDACs) that catalyze the hydrolytic removal
of acetyl group of lysines. In humans, HDACs are divided
into four classes (Table 1) based on their homology to yeast
HDACs [7, 8]. Class I HDACs include HDAC1, 2, 3, and 8;
these are related to the yeast enzyme Rpd3. Class II HDACs
include HDAC4, 5, 6, 7, 9, and 10, which are related to the
yeastproteinHDA1(histonedeacetylase-A1);classIIHDACs
are further divided into two subclasses—IIa (HDAC4, 5,
7, and 9) and IIb (HDAC6 and 10)—according to their
structural similarities. Class III HDACs are referred to as
sirtuins owing to their homology to the yeast HDAC Sir2.
This class includes SIRT1–SIRT7 [9, 10]. HDAC11, the most
r e c e n t l yi d e n t i ﬁ e di s o f o r m ,i sac l a s sI VH D A Cd u et oi t s
distinct structure [11]. Class I, II, and IV are zinc-dependent
enzymes whereas class III HDACs are nicotinamide adenine
dinucleotide (NAD+)-dependent enzymes. Based on their
various subcellular localization, intratissue variation, and
nonredundant activity, the diﬀerent HDACs are implicated2 Journal of Biomedicine and Biotechnology
in various speciﬁc cellular processes, such as proliferation,
metabolism, and diﬀerentiation. Forexample, class I HDACs
are mainly nuclear enzymes whereas class II HDACs localize
either to the cell nucleus or to the cytoplasm, depending
on their phosphorylation and subsequent binding of 14-
3-3 proteins. Moreover, class I HDACs are ubiquitously
expressed [12–15] whereas class II HDACs display a tissue-
speciﬁc expression.
To date, more than 15 HDACIs have been tested in
preclinical and early clinical studies for cancer therapy [16].
Many of them are broad-spectrum- or pan-HDACIs which
inhibit many of the Class I, II, and IV isoforms, includ-
ing suberoylanilide hydroxamic acid (SAHA), trichostatin
A (TSA),and valproic acid (VPA). Some clinical compounds
such as MS-275, FK-228, and apicidin have been termed as
“Class I-selective”, since they target several Class I isoforms
of HDAC. Tubacin is one of a few HDACIs that have
been reported as HDAC6-speciﬁc inhibitor [18]. Suramin,
a class III HDAC inhibitor for SIRT1, SIRT2, and SIRT5,
is a polysulfonated polyaromatic symmetrical urea with
antiproliferative and antiviral activity [17]( Table 1). So far,
almost all of the studies focus on class I and class II HDACs
[19], and a few focus on class III/sirtuins.
1.2. Protein Acetylation Balance. Signals that enter the cell
nucleus encounter chromatin where gene expression takes
place. Regulation of gene expression has two components
that act in concert: alteration of chromatin structure gov-
erned by histone modiﬁcation and binding by transcription
factors (TFs) including activators and repressors. Most
importantly, two classes of enzymes control the alteration
and binding:HAT andHDAC.HATmodify corehistone tails
byposttranslationalacetylationofspeciﬁclysineresiduesand
create appropriate “histone code” for chromatin modiﬁca-
tion to enhance DNA accessibility of TFs. In general, acety-
lation of core histones unpacks the condensed chromatin
and renders the target DNA accessible to transcriptional
machinery, hence contributing to gene expression. In most
cases, the TFs can also be acetylated by HAT to facilitate
their interactions with DNA and other proteins for trans-
activation. By contrast, deacetylation of the histones and TFs
by HDAC increases chromatin condensation and precludes
binding between DNA and TFs, leading to transcriptional
silencing. In normal conditions, protein concentration and
enzyme activity of HAT and HDAC remain in a highly
harmonized state of balance, which is named as “acetylation
homeostasis” to emphasize the importance of regulated
acetylation in acceding cellular homeostasis [20]. Recent
studies have shown that during various neurodegenera-
tive challenges, the balance is disturbed by loss of HAT
activity while the ratio of HAT to HDAC tilts in favor
of HDAC. The impaired acetylation homeostasis can cause
transcriptional dysfunction and facilitate neurodegenerative
cascade,which hasbeenimplicatedinpathogenesisofseveral
neurodegenerative disorders [21, 22]. Indeed, perturbation
of acetylation homeostasis is emerging as a central event in
the pathogenesis of neurodegeneration. Recent studies have
demonstrated HDACIs to be protective in animal models of
Huntington’s disease [23–26], amyotrophic lateral sclerosis
[27, 28], experimental autoimmune encephalitis [29], spinal
muscular dystrophy [30, 31], and others [32].
Recently, HDACIs have emerged as potent prosurvival
and anti-inﬂammatory drugs, oﬀering new lines of ther-
apeutic intervention for hemorrhagic shock and septic
shock. We and other groups have found that HDACIs such
as VPA, SAHA, and TSA prevent hemorrhage-associated
lethality in a rat and swine models of hemorrhagic shock
[3,4,33],suppressexpressionofproinﬂammatory cytokines,
and improve survival in a mouse model of septic shock
[5, 34, 35]. We have also demonstrated that inhibition
of HDAC can modulate the immune response following
trauma/hemorrhage andinﬂammatory secondhit inanimals
andhumans[36].This paperhighlightstheemergingrolesof
HDACIsasacetylationmodulatorsinmodelsofhemorrhagic
shock and septic shock, and explains some contradictions
encountered in previously published results.
2.HDACIsinHemorrhagicShock
HS represents a global ischemic stress, resulting from acute
blood loss. Current treatment for HS focuses on pathophysi-
ology at the level of organ systems: to maintain suﬃcient tis-
sue perfusion and vital organ function through administra-
tionofﬂuidsandbloodproductsandtosurgicallycontrolthe
source of hemorrhage. Unfortunately, this resource intensive
protocol remains diﬃcult to administer, particularly in
austereenvironments,where advancedsurgicalinterventions
may not be immediately available [37]. Moreover, this
approach fails to address much of the damage that takes
place at the cellularlevel as a result of hypoperfusion (during
hemorrhage) and reperfusion (during resuscitation) [38].
Focusing on the cellular pathophysiology of hemor-
rhagic shock, our laboratory has explored the strategy of
pharmacologic resuscitation with HDACIs as the protective
agents. HDACIs alter the acetylation status of proteins and
t h e r e f o r eh a v et h ep o t e n t i a lt om o d u l a t et h eg e n o m i ca n d
proteomic changes induced by hemorrhage. We have shown
that HDACIs can dramatically improve survival in lethal
models of hemorrhagic shock in rat [39, 40]a n ds w i n e
models [41]. Moreover, these inhibitors can protect cells
from apoptosis and suppress expression of proinﬂammatory
cytokines [5, 42, and Fukudome et al., unpublished data].
The cell protective mechanisms involve (1) epigenetic
regulation through post translation modiﬁcation of histone
proteins, (2) activation of cell survival factors such as
the PI3-kinase/Akt signaling pathway, (3) blockage of gut-
liver/lymph-lung axis, and (4) inhibition of inﬂammatory
mediators such as the Toll-like Receptor 4 (TLR4) signaling
pathway. All of these actions directly or indirectly involve
restoration of protein acetylation.
2.1. Acetylation-Related Epigenetic Regulation. Control of
epigenetic regulation with induction of histone acetylation
is the strategy to restore and maintain the normal ratio of
HAT/HDAC for treatment of many diseases. A number
of preclinical studies have demonstrated that HDACI can
improvesurvivalindegenerativediseases,preventbrainfrom
various insults, attenuate the eﬀects of aging, and increaseJournal of Biomedicine and Biotechnology 3
Table 1: Classiﬁcationof HDACs and selected HDACIs.
HDAC Class HDAC
isoforms Localizationof HDAC Speciﬁc HDAC inhibitors Nonspeciﬁc HDAC inhibitors References
Class I HDAC1 Nucleus MS-275, FK-228 TSA
[9, 16] (Zn++-dependent) HDAC2 Nucleus FK-228, apicidin SAHA
HDAC3 Nucleus MS-275, Apicidin Butyrate
HDAC8 Nucleus Valproic acid
Class IIa HDAC4 Nuc/Cyt TSA
SAHA
Butyrate
Valproic acid
[9, 16] (Zn++-dependent) HDAC5 Nuc/Cyt
HDAC7 Nuc/Cyt
HDAC9 Nuc/Cyt
Class IIb HDAC6 Mainly Cyt Tubacin TSA
SAHA [16]
(Zn++-dependent) HDAC10 Mainly Cyt
Class III SIRT1 Nuc/Cyt Suramin
Nicotinamide [9, 17]
(NAD+-dependent) SIRT2 Nuc/Cyt Suramin, AGK2
SIRT3 Nuc/Mitoch∗
SIRT4 Mitochondria
SIRT5 Mitochondria Suramin
SIRT6 Nucleus
SIRT7 Nucleus
Class IV
(Zn++-dependent) HDAC11 Nuc/Cyt TSA
SAHA [16]
life span [23, 43–45]. Our group has reported that admin-
istration of HDACIs protects organs and cells from lethal
hemorrhagic shock-induced injury [36, 42, 46, 47]. Several
converging lines of inquiry suggest that the protective
mechanism of HDACIs may result from the fact that alter
the response to ischemic injury and reduce damage in the
important organs during the progress of hemorrhagic shock.
Intheheart,ischemiainduceshistonedeacetylaseactivity
via deacetylation of histones H3/4 in vitro and in vivo [48].
Usingstandard murine model ofheart ischemia-reperfusion,
Granger. demonstrated that HDACI signiﬁcantly reduce
infarct area, evenwhen delivered 1h after the ischemic insult.
HDACI decrease the response to ischemic injury and lessen
the size of myocardial infarction [48] .I np a r t ,t h i si st h r o u gh
prevention of ischemia-induced activation of gene programs
that include hypoxia inducible factor-1α, cell death, and by
decreasing vascular permeability in vivo and in vitro,w h i c h
reduces vascular leak and myocardial injury.
In the liver, low oxygen increases HDAC1, 4, and 5
protein levels by 2-fold and decreases acetylated histone
H3 levels to 50%–75% of the control values in a turtle
model of anoxia [49]. In a rat model of hemorrhagic shock,
Gonzales reported that hemorrhage increased serum levels
oflactate, lactatedehydrogenase, aspartate aminotransferase,
and alanine aminotransferase. Alternatively, treatment with
VPA (an HDACI) induced acetylation of histones (H2A, H3,
and H4), and alleviated serum levels of these enzymes and
prolongedsurvival (ﬁvefold).Furthermore, hyperacetylation
of the histone proteins indicated the presence of active
genes and correlated with improved survival [50]. Gene
expression proﬁling data from our group, in comparison
to HS without treatment, has shown that VPA treatment
upregulates expression of 17 genes at the early stage of
HS, compared to HS without treatment (Fukudome et al.,
unpublished data). Two of these genes are peroxisome
proliferator-activated receptor γ coactivator-1α (PGC-1α)
anddualspeciﬁcityproteinphosphatase5(DUSP5).PGC-1α
protects cells from oxidative stress by increasing expression
of various antioxidant defense enzymes including superox-
ide dismutase and glutathione peroxidase [51]. DUSP5 is
an inducible, nuclear, dual-speciﬁcity phosphatase, which
speciﬁcally interacts with and inactivates the extracellular
signal-regulated kinase (ERK) 1/2 MAP kinases in mam-
malian cells [52]. Inactivation of ERK1/2 MAP kinases by
DUSP5 may be one of the mechanisms responsible for the
protective properties of VPA in HS.
In the kidney, it has been discovered that ischemia/reper-
fusion induces a transient decrease in histone acetylation in
proximal tubular cells. This is likely a result of a decrease in
histoneacetyltransferase activityas suggestedbyexperiments
with energy-depleted renal epithelial cells in culture [53].
During recovery after transient energy depletionin epithelial
cells, the HDAC isozyme HDAC5 is selectively downreg-
ulated in parallel with the return of acetylated histone.
Knockdown of HDAC5 by RNAi signiﬁcantly increased his-
tone acetylation and bone morphogenetic protein-7 (BMP7)
expression [53]. In a rat model of HS, it was found that
treatment of animal with VPA or SAHA markedly increases
phosphorylation of Akt and decreases the expression of
proapoptotic BAD (Bcl-xl/Bcl-2 associated death promoter)4 Journal of Biomedicine and Biotechnology
p r o t e i ni nk i d n e yt i s s u e[ 54]. Further investigation is needed
toﬁnd ifthereisanyrelationship betweenHDAC5inhibition
and Akt activation.
In the brain, Faraco found that in the ischemic brain
(subjected to 6h of middle cerebral artery occlusion),
histone H3 acetylation levels are dramatically decreased
without evidence of a concomitant change in histone acetyl-
transferase or deacetylase activities. Treatment with SAHA
(50mg/kg i.p.) increased histone H3 acetylation within
the normal brain (of approximately 8-fold after 6h) and
prevented histone deacetylation in the ischemic brain. These
eﬀects were accompanied by increased expression of the
neuroprotective proteins heat-shock protein 70 (Hsp70) and
B-cell lymphoma 2 (Bcl-2) in both control and ischemic
braintissue24hafter theinsult.At thesame time point,mice
injected with SAHA at 25 and 50mg/kg had smaller infarct
volumes compared with vehicle-receiving animals (28.5%
and 29.8% reduction, P<. 05 versus vehicle). Recently, Li
reported that VPA treatment induces acetylation of histone
H3,increasesexpression ofβ-catenin andBcl-2proteins, and
prevents neuronal apoptosis in in vitro hypoxic condition
(0.5% O2)a sw e l la si nt h ein vivo model of HS [42].
These ﬁndings demonstrate that pharmacological inhibition
of HDAC promotes expression of neuroprotective proteins
within the ischemic brain and underscores the therapeutic
potential of molecules inhibiting HDAC for HS-induced
brain injury.
2.2. Eﬀect of HDACIs on Phosphoinositide 3-Kinase (PI3K)-
Akt/PKB Pathway. Activation of PI3K enhances cell survival
and antagonizes apoptosis via Akt/PKB activity in many cell
types including cardiomyocytes, cardiac ﬁbroblast, vascular
smooth muscle cells (VSMCs), endothelial cells and hepa-
tocytes [41, 55, 56]. Alam recently found that VPA exerts
antiapoptotic eﬀect through the Akt/PKB signaling pathway
and improves survival in a swine model of traumatic
hemorrhagic shock [41]. In this in vivo study, they compared
cell protective eﬀects of the HDAC inhibitor (VPA) with
resuscitation using fresh whole blood (FWB) and a normal
salinecontrol.VPAtreatmentincreasedthelevelsofactivated
Akt, deactivated glycogen synthase kinase-3β (GSK-3β), β-
catenin, and Bcl-2 signiﬁcantly when compared to FWB and
saline control groups. However, the total Akt and total GSK-
3β levels did not diﬀer across the three treatments [41]. VPA
has been reported to directly and indirectly inhibit GSK-
3β [57]. However, it is not clear how the HDACI inﬂuences
the Akt signaling in an animal model of trauma and hem-
orrhagic shock. There are several other possibilities for this
pathwayactivationinadditiontodirectinhibitionofGSK-3β
(Figure 1).
2.2.1. An Increase of Acetylated Tribbles (TRB) 3 and Phos-
phatase and Tensin Homolog (PTEN) May Be Associated
with PI3K/Akt Activity [58]. G r o w t hf a c t o r ss u c ha si n s u l i n ,
insulin-like growth factor 1 (IGF-1), erythropoietin, and
cytokines that reduce apoptosis rely almost exclusively on
the PI3K/Akt pathway whereas GPCR-induced PI3K/Akt
activation and cardioprotection occurs in response to sev-
eral peptide agonists, including urocortin, ghrelin, and
adrenomedullin as well as beta2-adrenergic receptor (β2-
AR) stimulation [55, 59–61]. In the heart, overexpression
of Akt/PKB causes resistance to apoptosis [55]; knockout of
Akt2/PKBβ enhances apoptosis in response to myocardial
ischemia [62]. Consistent with a critical role for Akt/PKB
in cell survival, loss or gain of TRB3 and PTEN activ-
ity leads to reduced or enhanced apoptosis, respectively
[63, 64]. Alternatively, increased expression of TRB3 and
PTEN promotes apoptosis in cardiac myocytes [63, 65].
PTEN is a dual protein/lipid phosphatase whose main
substrate is phosphatidylinositol 3,4,5-triphosphate (PIP3),
the product of PI3K. PTEN degrades PIP3 to an inac-
tive form phosphatidylinositol 4,5-bisphosphate (PIP2) [55,
66–68], inhibiting Akt activation. PTEN is constitutively
active and is the major downregulator of PI3K/Akt [69].
PTEN also forms signaling complexes with PDZ domain-
containing adaptors, such as the MAGUK (membrane-
associated guanylate kinase) proteins. These interactions
appear to be necessary for the metabolism of localized pools
of PIP3 involved in regulating actin cytoskeleton dynamics.
Acetylation is a major mechanism that regulates PTEN
activity [70]. Histone acetylase p300/CREB-binding protein-
associated factor (PCAF) interacts with PTEN and acetylates
lysines 125 and 128 which are located within the catalytic
cleft of PTEN and are essential for PIP3 speciﬁcity. PCAF
f u n c t i o n sa san e g a t i v er e g u l a t o ro fP T E N[ 71]. TRB3 is
an intracellular pseudokinase that modulates the activity of
severalsignal transductioncascades. TRB3hasbeenreported
to inhibit the activity of Akt protein kinases [72]. TRB3
gene expression is highly regulated in many cell types, and
hypoxia or endoplasmic reticulum (ER) stress promotes
TRB3 expression. TRB3 binds to inactive and unphospho-
rylated Akt, thus preventing its phosphorylation [73]. It
remains unknown whether and how PCAF regulates TRB3.
Recently,Yao and Nyombareported that acetylation status of
TRB3 and PTEN is decreased in association with increased
HDAC and decreased HAT activities. The hypoacetylated
TRB3andPTENcaninhibittheAkt-activityinaratmodelof
prenatal alcohol exposure [58], which suggests that HDACI
treatment could inhibit the activity of TRB3 and PTEN, and
therefore enhance Akt signaling.
2.2.2. Induction of Hsp70 by HDACIs May Be Associated with
the PI3K/Akt Pathway. In a rat model of hemorrhagic shock,
Gonzalesfound thatVPAtreatment increased theacetylation
of nonhistone and histone proteins and expression of Hsp70
in rat myocardium, and signiﬁcantly prolonged survival
(5 fold) compared to the nontreatment control [4]. In
rat cortical neurons, VPA treatment markedly upregulated
Hsp70 protein levels, and this was accompanied by increased
Hsp70 mRNA levels and promoter hyperacetylation and
activity [74]. Other HDAC inhibitors—sodium butyrate,
trichostatin A, and Class I HDAC-speciﬁc inhibitors MS-275
and apicidin—all possess the ability to induce HSP70.
Hsp70 is a molecular chaperone, cell-protective, and
anti-inﬂammatory agent. Marinova recently reported that
HDACIs increase Sp1 acetylation, and promote the associ-
ation of Sp1 with the histone acetyltransferases p300 and
recruitment of p300 to the Hsp70 promoter. Furthermore,Journal of Biomedicine and Biotechnology 5
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Figure 1: Eﬀect of HDACIs on cell survival in hemorrhagic shock. HDACIs induce phosphorylation of AKT by inhibition of TRB3 and
PTEN. While AKT stimulates transcription of cell survival genes through several other pathways, phosphorylated AKT also phosphorylates
GSK-3β. Phosphorylated GSK-3β becomes inactivated form, which cannot degrade β-catenin. HDACIs (e.g., VPA) can also directly inhibit
GSK-3β. Moreover, HDACIs induce acetylation and nuclear translocation of β-catenin, leading to downstream survival gene transcription.
P, phosphorylation; Ac, acetylation.
HDACI-inducedcellprotectioncanbepreventedbyblocking
Hsp70 induction [74]. In addition, Gao and Newton showed
that Hsp70 directly binds and stabilizes Akt/PKB as well as
protein kinase A and protein kinase C, thus prolonging the
signaling lifetime of the kinases [75]. Taken together, these
ﬁndings suggestthatthePI3K/AktpathwayandSp1arelikely
involved in Hsp70 induction by HDACIs, and this induction
may in turn interact with Akt/PKB to sustain the active state
of Akt to protect the cells from apoptosis.
In addition to the interaction with the Akt/PKBpathway,
Hsp70 also directly interacts with diﬀerent proteins of the
tightly regulated programmed cell death machinery, thereby
blocking the apoptotic process at distinct key points. For
example, Hsp70 can inhibit the apoptotic cascade [76, 77],
decrease formation of the functional apoptosome complex
[78, 79], prevent late cascade-dependent events such as
activation of cytosolic phospholipase A2 and changes in
nuclear morphology, and protect cells from forced expres-
sion of caspase-3 [80]. Moreover, Hsp70 inhibits c-Jun N-
terminal kinase (JNK)-mediated cell death by suppressing
JNK phosphorylation either directly and/or through the
upstream SEK kinase [81–83], and hampers TNF-mediated
apoptosis by inhibition of ASK-1 [84].
It has been noted that Hsp70 has diﬀerent functions
depending on its intracellular or extracellular location.
Intracellular Hsp70 has a protective function which allows
the cells to survive lethal conditions [85]. Extracellularly
located or membrane-bound Hsp70 mediates immunolo-
gical functions. They can elicit an immune response and will
be discussed later.
2.3. Eﬀect of HDACIs on Gut and Lung in Hemorrhagic
Shock. Hemorrhagic shock is characterized by insuﬃcient
tissue perfusion which is needed to meet the oxygen and
nutrient demands of cells. The host response to hemorrhagic
shock involves a coordinated expression of mediators that
act both locally and systemically with profound eﬀects on
organ function. The accumulated evidences suggest that
gut and lung, especially gut, represent important site(s) of
immune mediator production and inﬂammation. Although
two major hypotheses, gut-lymph-lung axis [86, 87]a n d
gut-liver-lung axis [88, 89], have brought much debate
based on the diﬀerent ﬁndings, it is clear that hemorrhagic
shock is associated with intestinal ischemia which makes gut
a proinﬂammatory organ. For the fact that most of these
mediators are produced by cells of the immune system,
signiﬁcant immunoregulatory actions occur within the gut-
liver and/or lymph-lung axis and in peripheral immune sites
(Figure 2). It is well established that the gut plays a pivotal
pathogenic role in the pathogenesis of SIRS and multiorgan
dysfunction syndrome (MODS) [90, 91].
It is clear that gut ischemia can cause lung injury,
b u th o wc a ni tb ep r e v e n t e d ?W ep r o p o s e dt h a tH D A C I s
could protect lung from gut-originated damage. To test this6 Journal of Biomedicine and Biotechnology
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Figure 2: Eﬀect of HDACIs on gut-liver/lymph-lung axis in response to hemorrhagic shock. Hemorrhagic shock causes destruction of the
gut barrier due to tight junction protein (e.g., claudin-3) loss. Bacteria, endotoxin, and inﬂammatory cytokines enter into circulation and
lung. In the lung tissue, MAPKs are stimulated and neutrophils inﬁltrated, resulting in acute lung injury. HDACIs block these processing by
inhibition of tight junction protein loss in gut and inactivation of MAPKs in lung.
proposal, the superior mesenteric artery (SMA) of rats was
clamped for 60min to induce ischemia and then released for
reperfusion. Without any treatment, gut ischemia induced
production of proinﬂammatory cytokines or prostaglandin-
like compound such as IL-6, cytokine-induced neutrophil
chemoattractant (CINC), 8-isoprostane in lung tissues, and
increased neutrophil lung inﬁltration. However, treatment
with VPA signiﬁcantly reduced these mediators in lung
tissues and improved survival in a rat model of ischemia
and reperfusion (Kim, unpublished data). It is not clear how
VPA protects gut from ischemic damage and prevents acute
lung injury. However, based on our recent ﬁndings, it is
conceivable that VPA maintains gut barrier in part through
stabilizing intestinal tight junctions (TJ) (Figure 2).
The function of gut barrier is based on intestinal tight
junctions. Encircling epithelial cells, the intestinal TJ is
a region where the plasma membrane of epithelial cells
forms a series of contacts that appear to completely occlude
the extracellular space and create an intercellular barrier
and intramembrane diﬀusion fence [92]. Normally, TJ is
anchored in the cell via TJ proteins and ﬁlamentous actin (F-
actin) cytoskeleton. Hypoperfusion, or ischemia, can cause
disruption of F-actin cytoskeleton with subsequent TJ loss
and barrier failure. Bacterialt r a n s l o c a t i o nt om e s e n t e r i c
lymph nodes, liver, and spleen is found at a very early
stage of hemorrhagic shock [89]. Loss of gut wall integrity
not only leads to paracellular leakage of microbial products
[93, 94] but also contributes to the development of systemic
inﬂammation and distant organ failure [95].
O n eo ft h em a j o rT Jp r o t e i n si sc l a u d i n - 3 .A l t h o u g ht h e
exact function of claudin-3 within TJ is not completely clear,
itappears tobeimportantinTJformation andfunction[96].
Recent studies from our group [97]a n do t h e r s[ 89]h a v e
shown that HS leads to destruction of the gut barrier due to
TJ protein loss. Also, it was found that the claudin-3 protein
is released into circulation very early (30–60min) after the
onset of HS [97]. Alternatively, CINC, a chemokine that
promotes neutrophil chemotaxis, is signiﬁcantly elevated
in serum and lung tissue with increased myeloperoxidase
(MPO) levels at 4h after hemorrhage. However, VPA treat-
ment reverses HS-induced claudin-3 loss from the intestine
and reduces the levels of CINC and MPO in serum and
lung signiﬁcantly (Fukudome, unpublished data). These
ﬁndings suggest that VPA can stabilize claudin-3 in gut TJ,
maintain the intestinal barrier, and prevent harmful gut-
derivedsubstancesfromgettingintothesystemiccirculation.
Furthermore, we recently demonstrated that sublethal
hemorrhagic shock (40% blood loss) results in phosphory-
lation (activation) of ERK, JNK and p38 mitogen-activated
p r o t e i nk i n a s e( M A P K )i nl u n gt i s s u e sa t1a n d4h o u r s
compared to the sham group. Postshock administration of
VPA (300mg/kg, iv) signiﬁcantly attenuates the MAPK acti-
vation but does not aﬀect expression of total ERK, JNK and
p38 proteins [98]. These kinases are globally expressed and
known to be key regulators of stress-mediated cell fate deci-
sion.Activationoftheseproteinshasbeenstronglyassociated
with poor outcomes while inhibition of MAP kinases has
been associated with survival in hemorrhage models [98].Journal of Biomedicine and Biotechnology 7
VPA can also directly modulate MAPK activation. Cao
has studied the eﬀects of HDACI treatment on LPS-
induced activation of p38 MAPK and found that HDACIs
inhibit p38 phosphorylation. In this experiments, HDACIs
induce acetylation of MAP kinase phosphatase-1 (MKP-1),
a protein that dephoaphorylates MAPK and inactivates
MAPK pathways. These results demonstrated that HDACI
treatment and MKP-1 acetylation increases the interac-
tion between MKP-1 and p38 MAPK, and results in p38
inactivation, reduced inﬂammation and increased survival
among LPS-exposed mice [34]. Whether similar acetylation-
mediated mechanisms exist for the regulation of ERK and
JNK is still unknown but is highly plausible.
3.HDACIsinSepticShock
The progression of infection to septic shock begins with the
release ofinﬂammatory mediatorsatthelocalsite ofmicrobe
invasion. This inducesthe migration ofwhite blood cells and
platelets to the infection site and contributes to endothelial
damage and increased microvascular permeability. Blood
ﬂow is also reduced which sets the stage for ischemia-
reperfusion injury. These physiologic processes are part of
the exaggerated SIRS, which can lead to MODS.
Many of the body’s reactions to infection with gram-
negative organisms are due to lipopolysaccharide (LPS),
a component of the outer bacterial cell wall membrane,
also referred to as endotoxin. It can induce septic shock
physiology and has been used extensively to produce shock
in laboratory models. LPS exerts the downstream signals
through the Toll-like Receptor-4 (TLR4). TLR4 activates
two downstream pathways: Myeloid diﬀerentiation factor
88 (MyD88)-dependent and MyD88-independent pathways.
The former leads to the production of proinﬂammatory
cytokinessuchasIL-6, TNF-α, and IL-12with thequickacti-
vation of nuclear factor-kappaB (NF-κB) and MAPK. The
MyD88-independent pathway is associated with activation
of interferon (IFN) regulatory factor 3 (IRF3), subsequent
induction of IFN-β, and maturation of dendritic cells.
It has been shown that HDACIs exert anti-inﬂammatory
activities via the suppression of inﬂammatory cytokines and
nitric oxide[99]. In LPS-stimulated human peripheral blood
mononuclear cells, HDACI (ITF2357) reduces the release of
TNF-α,I L - 1 β,a n dI F N - γ [100]. Other HDACIs such as TSA
andSAHAhavebeenshowntodecreaseLPS-inducedinﬂam-
mation in mice [5, 34, 101]. In RAW 264.7 cells, treatment
ofthe macrophages with SAHAsigniﬁcantly suppresses LPS-
induced gene expression and protein production of IL-1β,
IL-6, and TNF-α [5, 101]. In an in vivo rodent model of
septic shock, HDACIs attenuate acute lung and liver injury
and improve survival [35, 101, 102]. Further mechanistic
studies have demonstrated that HDACIs play an important
inhibitory role in TLR-4-MyD88 signaling pathways via NF-
κB and MAPKs. Protein acetylation provides a key for the
control of inﬂammatory response (Figure 3).
3.1. HDACIs Aﬀect NF-κB Activity. NF-κBi sa nu b i q u i t o u s l y
expressed transcription factor that plays an important role
in innate immunity and other critical processes. The NF-
κB family consists of p50, p52, p65 (Rel A), c-Rel, and
Rel B, which form homo- or hetero-dimers. The p50/p65
heterodimer is the most frequently found combination in
mammals. Inactive NF-κB complexes are retained in the
cytoplasm by the IκB inhibitor. In innate immune signaling,
host cells can respond to the threat of bacterial pathogens
(e.g.,LPS)via extracellular receptorTLRs(e.g.,TLR4).TLR4
interacts with MyD88 and recruits interleukin-1 receptor-
associated kinase 1 (IRAK1) and IRAK4 to the receptor
complex. IRAK1 phosphorylates TNF receptor-associated
factor 6 (TRAF6) leading to the activation of the IκBk i n a s e
(IKK). The activation of IKK results in IκB phosphorylation,
triggering its ubiquitination and proteasomal degradation.
Free NF-κB then translocates to the nucleus to regulate the
transcription ofchemokines,cytokines,andotherinﬂamma-
tory response molecules [103].
In the nucleus, p50 and p60 can be regulated by acety-
lation. The function of acetylated NF-κBi sc o m p l i c a t e d .
Acetylationofp50at K431,K440,and K441promoteshigher
DNA-binding aﬃnity towards NF-κB target sequences cor-
relating with increased p300 (histone acetyltransferase)
recruitment and transcriptional activation [104, 105]. The
p300 can acetylate p65 at multiple lysine residues and result
in diﬀerent consequence. Acetylation of p65 at K221 and
K310 is associated with an increased transcription of NF-κB
target genes [106] and is required for the full activity of p65
[107]. In contrast, HDAC1 and HDAC3 deacetylate p65 at
either K221 or K310, resulting in the inhibition of NF-κB.
Additionally, K122 and K123 acetylation reduces p65 DNA-
binding aﬃnity accompanied with increased IκBi n t e r a c t i o n
and nuclear export [108]. The p300-mediated acetylation of
K314 and K315 in p65 has no obvious eﬀect on NF-κBD N A
binding or translocation.
Indeed, HDACIs have been shown to induce hyperacety-
lation and repress NF-κB signaling and expression of several
target genes [109–111]. Conversely, other groups reported
that HDACIs enhance NF-κB-dependent gene expression
but were in the presence of TNFα [112–115]. Presumably,
inhibitory or enhancive eﬀects of HDACIs on NF-κBr e l yo n
the cell type, expression of a diﬀerent set of HDAC isoforms,
acetylation/deacetylation of NF-κBa td i ﬀerent lysine or by
diﬀerent enzyme, as well as the source of cell stimulation
(e.g., LPS, cytokines and high glucose levels) [99].
3.2. HDACIs Inhibit MAPK Activity. In mammalian cells,
JNK and p38 MAPKs activate mitogen and stress-activated
protein kinase 1 (MSK1) such as ribosomal S6 kinase 2
(RSK2). RSK2 has a strong activity towards phosphorylation
ofhistoneH3atSer10[116].The phosphorylation ofhistone
H3 occurs on the promoters of the subset on the stimulus-
induced cytokine and chemokine genes, recruits NF-κBt o
the promoters, and stimulates transcription of inﬂammatory
genes such as IL-6, IL-8, IL-12, and macrophage chemo-
attractant protein 1 (MCP-1) [117].
It has been reported that HDAC inhibitor TSA enhances
the activity of mitogen-activated protein kinase phospho-
tase-1 (MKP-1) [34, 118].MKP-1 is anuclear-localized dual-
speciﬁcity phosphatase and preferentially dephosphorylates8 Journal of Biomedicine and Biotechnology
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Figure 3: TLR4 signaling – a converged immune response pathway for hemorrhagic shock and septic shock. TLR4 not only serves as a key
sensorof pathogen-associatedmolecular patterns (PAMPs)but alsois proposed recently to act as a receptor forsomeendogenous molecules
called “alarmins”.HDACIs block TLR4 signalingat multiple steps; therefore, they can inhibit immune response for both hemorrhagic shock
and septic shock.
MAPKs such as p38 and JNK. Recently, Cao showed that
MKP-1 interacts with HAT and that acetylation of MKP-1
inhibits TLR4 signaling [34]. They immunoprecipitated the
histoneacetylase p300andshowed that itwas associated with
MKP-1. Moreover, MKP-1 was acetylated by p300 on lysine
residueK57withinitssubstrate-bindingdomain.Acetylation
ofMKP-1 induced by TSA enhanced the interaction between
MKP-1 and p38 MAPK, suggesting that HDACI could
increase the phosphatase activity and inactivate p38 MAPK.
Indeed, TSA increased MKP-1 acetylation and blocked
MAPK signaling in wild-type (WT) cells. However, TSA had
no eﬀect in cells lacking MKP-1. Furthermore, TSA reduced
inﬂammation and mortality in WT mice treated with LPS,
but failed to protect MKP-1 knockout mice. These ﬁndings
suggest that acetylation of MKP-1 inhibits innate immune
signaling, and targeting the MAPK pathway by HDACI may
be an important approach in the treatment of septic shock.
Recently, our group has found that HDAC inhibitor
SAHAcan reduce the expression of MyD88 gene and protein
in vitro and in vivo after LPS insult [101]. Moreover, SAHA
acetylates heat shock protein 90 (Hsp90) and deassociates
the protein from IRAK1, resulting in IRAK1 degradation
(Chong,unpublished data). Our new ﬁndings have provided
evidence that inhibition of HDAC can block, at least in part,
activityofNF-κBandMAPKsintheinitialstepsoftheTLR4-
MyD88- NF-κB/MAPK pathway (Figure 3).
3.3. TLR4 Signaling – a Converged Immune Response Pathway
for Hemorrhage and Sepsis. Hemorrhage and sepsis activate
severalinﬂammatory and innate immune signaling pathways
[119]. Systemically, these pathways promote recruitment of
neutrophils and release of inﬂammatory cytokines [120].
Within the cells, the inﬂammatory stimuli induce MAPK-
dependent phosphorylation or phosphoacetylation of his-
tone proteins and modulate the epigenetic accessibility of
DNA in the cell [117]. Downstream, these signals change the
gene expression proﬁle of the cells insulted with hemorrhage
or sepsis, altering the competing signals (e.g. prosurvival
and prodeath, or anti-inﬂammation and proinﬂammation),
that ultimately determine their fate. Two key pathways
in hemorrhage- and sepsis-induced cellular injuries are
the mitogen activated protein (MAP) kinase and NF-κB
pathways. These proteins, ERK1/2, JNK, p38 protein kinase,
and NF-κB, are globally expressed and known to be key
regulatorsofcellfate decisions[121,122],which areinvolved
in TLR4 signaling pathway.
It is well known that mammalian TLR4 serves as a key
sensor of pathogen-associated molecular patterns (PAMPs)Journal of Biomedicine and Biotechnology 9
such as LPS. More recently, an additional role for TLR4
has been proposed. A number of reports have emerged to
suggest that diverse molecules of host-cell origin may also
serve as endogenous ligands of TLR4 [2, 123, 124]. These
molecules represent members of a recently identiﬁed family
of molecules, including Hsp70, ﬁbrinogen, high-mobility
group box 1 (HMGB1), nucleolin, and annexins [123]. They
have been found to serve as mediators of inﬂammation that
may be expressed or released in response to tissue damage
from trauma including HS. These molecules have been
described as “alarmins”, which are the equivalent of PAMPs
but are endogenous molecules. They are rapidly released
following nonprogrammed cell death but are not delivered
by apoptotic cells. Immune cells can also be induced to
produce and release alarmins without dying. Generally,
this is done by using specialized secretion systems or by
the endoplasmic reticulum (ER)-Golgi secretion pathway.
Endogenous alarmins and exogenous PAMPs can be con-
sidered subgroups of a larger family of damage-associated
molecular patterns (DAMPs). They conveya similar message
and elicit similar responses through TLR4 (Figure 3)l e a d i n g
to activation of MAPKs and NF-κBp a t h w a y s[ 123, 125].
HDACIs have been described above for their pro-
survival and anti-inﬂammatory properties. The combined
prosurvival and anti-inﬂammatory eﬀectiveness makesthem
a highly attractive choice for the treatment of lethal
hemorrhagic shock and its septic complications. In our
preliminary studies, wehavealready discoveredthatHDACIs
not only inhibit expression of proinﬂammatory cytokines
and chemokinesin cellsbutalso preventsome alarmins from
being released from cells in hemorrhagic shock and septic
shock (Li, unpublished data). Further investigation with
diﬀerent models (e.g., “two-hit” model) are being planned
to further clarify the precise mechanisms of action and the
role played by protein acetylation.
4.Contradictionand Explanation
Although most studies have demonstrated that HDACIs
induce expression of prosurvival/anti-inﬂammatory genes
and proteins, some authors have reported diﬀerent results
[126]. Wetzel et al. found that TSA causes inhibition of
glioma cell growth by both cell cycle arrest and apoptosis
[127], which contradicts the study of Avila et al. that
TSA increases neurons survival [31]. Aung et al. observed
that treatment of bone marrow-derived macrophages with
TSA enhances LPS-induced expression of proinﬂammatory
genes [128], which disagrees to the ﬁnding of Han and
Lee that TSA signiﬁcantly decreases mRNA and protein
levels of the proinﬂammatory cytokines in macrophages
[129]. This discrepancy of pro/anti-apoptosis and pro/anti-
inﬂammation may be due to diﬀerences in cell types, HDAC
isoform, acetylation/deacetylation of a protein by diﬀerent
enzymes or at diﬀerent lysine residues, and variances in the
type of cellular stimulation, and so forth [99].
For instance, HDACIs have been shown to potentiate
TNF-α expression in microglial cells [130] but to suppress
TNF-αexpression in culturedhuman peripheral bloodmon-
onuclear cells and macrophages in response to LPS [5, 131].
It is not clear how HDACIs function diﬀerently in these
diﬀerent cell types. However, there are numerous reasons for
the diﬀerentialeﬀectsofHDACIsbetween normal and trans-
formedcells.HDACIsinducediﬀerentphenotypesinvarious
transformed cells, including growth arrest, activation of the
extrinsic and/or intrinsic apoptotic pathways, autophagic
cell death, reactive oxygen species (ROS)-induced cell death,
mitotic cell death, and senescence. In comparison, normal
cells are relatively more resistant to HDACI-induced cell
death[132,133].In many transformed cells, ROS-oxidation-
reduction pathways are important mechanisms of HDACI-
inducedtransformed celldeath[134].Thioredoxin(Trx)acts
as a hydrogen donor required for the activation of many
proteins, including ribonucleotide reductase which is essen-
tial for DNA synthesis and transcription factors and is an
antioxidation scavenger of ROS [135]. HDACIs upregulate
the expression of Trx-binding protein 2 (TBP2) [136], which
bindsandinhibitsTrxactivity,andcancausedownregulation
of Trx in transformed but not normal cells [134, 136].
Trx is an inhibitor of apoptosis signal regulating kinase
1( A S K 1 )[ 137]. Therefore, inhibition of Trx by HDACIs in
transformed cells subsequently results in cell apoptosis.
Diﬀerential cellular expression of HDACs is another
factor that causes the discrepancy. The HDACs have been
found to interact with diﬀerent proteins and transcription
factors. HDAC1 interacts with retinoblastoma protein [138]
and SP1 [139]. HDAC2 interacts with NF-κB[ 140]. HDAC1
and HDAC2 also interact directly with DNA topoisomerase
II to modify topoisomerase activity [141]. HDAC3 interacts
with NF-κB[ 142]. HDAC4 and HDAC5 interact with
myocyteenhancerfactor2(MEF2)[143].Duetotheprotein-
protein interaction, inhibition of HDAC with diﬀerent
HDAC inhibitor results in diﬀerent outcome. In cultured
neonatal mouse cardiomyocytes, Zhu et al. have shown that
LPS insult increases HDAC3 activity and suppresses TNF-α
expression. The upregulation of HDAC3 activity was abro-
gated by a pan-HDAC inhibitor TSA and class I HDAC in-
hibitor apicidin, but not by class II HDAC inhibitors [142].
Posttranslational modiﬁcations of a protein by diﬀerent
enzymes or at diﬀerent amino acid residues can cause dif-
ferent results. For instance, phosphorylation of NF-κ-B p65
preferentially interacts with p300/CBP, an acetyltransferase,
resulting in p65 acetylation at multiple sites. Acetylation of
K221 and K310 is associated with an increased transcrip-
tion of NF-κB target genes [106], while K122 and K123
acetylation reduces p65 DNA-binding aﬃnity accompanied
with increased IκB interaction and nuclear export [108].
Deacetylation of p65 K310 by SIRT1 inhibits transcription
of NF-κBt a r g e tg e n e s[ 144], and deacetylation of p65 at
either K221 or K310 by HDAC1 and HDAC3 results in the
inhibition of NF-κB[ 145].
In addition, a study from Wilson and colleagues suggests
that the opposite eﬀects of HDACIs may result from the
eﬀects of acetylation on speciﬁc combinatorial interactions
required for eﬃcient transcription of individual genes [146].
They used the mouse mammary tumor virus (MMTV)
promoter to assess the consequences of inhibiting histone
deacetylaseactivityontranscriptional activationmediatedby
the progesterone receptor in vivo. In human breast cancer10 Journal of Biomedicine and Biotechnology
cells, TSA induced global histone hyperacetylation, and this
eﬀect occurred independently of the presence of the hor-
mone. Interestingly, chromatin immunoprecipitation anal-
ysis revealed no signiﬁcant change in the level of acetylated
histones associated with MMTV promoter following TSA
treatment. In these cells, the MMTV promoter adopted
a constitutively “open” chromatin structure. Treatment with
TSA converted the MMTV promoter into a “closed” chro-
matin structure, evicted the transcription factor nuclear
factor-1 from the promoter, and downregulated chromatin
remodeling proteins and coregulatory molecules known to
participate in the activation of the promoter-eﬀects that
occurred in the absence of histone acetylation of the local
promoter chromatin structure.
The eﬀects of HDACIs depend upon the “cell context”
which in turn inﬂuences acetylation or the interaction of
HDACs with histone and nonhistone proteins. Ideally, com-
prehensive consideration of cell type, activity of HDAC
isoforms and the nature of cell stimulation should be taken
into account when eﬀects of the inhibitor are examined in
an experimental model. Lack of attention to these details can
create an erroneous impression of contradictory results.
5.FuturePerspectives
Current therapies for massive hemorrhage and severe sepsis
largely focus on restoring tissue perfusion through resus-
citation but have failed to address the speciﬁc cellular
dysfunction caused by shock. Acetylation is rapidly emerg-
ing as a key mechanism that regulates the expression of
numerous genes (epigenetic modulation through activation
of nuclear histone proteins), as well as functions of multiple
nonhistoneproteinsinvolvedinkeycellularfunctionssuchas
cellsurvival, repair/healing,andanti-inﬂammation. HDACIs
hold great promise as a new class of agents for restoration of
protein acetylation and treatment of hemorrhagic and septic
shock.
Future studies should further elucidate the function of
individual HDAC isoforms in severe hemorrhage and in-
ﬂammation and assess potential eﬀects of HDACIs on sepsis
following hemorrhagic shock. Since individual HDAC iso-
formshavedistinctivephysiologicalfunctions,itisimportant
to develop next generation of HDACIs. The new HDACIs
could then target speciﬁc HDAC isoforms and presumably
would result in improved eﬃcacy relative to the ﬁrst gener-
ation pan inhibitors such as SAHA and TSA but with little
adverse eﬀects. In addition to being used as prosurvival
agentsforseveretrauma hemorrhage, HDACIscouldbeused
as the combinedprosurvival and anti-inﬂammatory drugs to
prevent hosts from sepsis and even to treat sepsis following
hemorrhage.
6.Summary
Experimental evidence has shown that treatment with
HDACIs increases endurance of animals subjected to lethal
blood loss. The survival beneﬁt is seen even when the drugs
are administered postinsult, and is reproducible in diﬀer-
ent species including large animal models of polytrauma.
Protective properties of HDACIs are not limited to hemor-
rhagic shock; HDACI treatment can also improve survival
in LPS models of septic shock. Administration of HDACIs
modulates the immune system to create a favorable pheno-
type not only during the acute phase of hemorrhagic shock
but also later when the septic complications are likely to
occur. Repeated successes of HDACIs in well-designed ani-
mal models of hemorrhagic shock (small and large animals)
and septic shock (pre- and postshock treatments) suggest
that modulation of protein acetylation is potentially a very
useful strategy for the treatment of these critical diseases.
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